2014
The KRAS-Variant and miRNA Expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905
Lee LJ, Ratner E, Uduman M, Winter K, Boeke M, Greven KM, King S, Burke TW, Underhill K, Kim H, Boulware RJ, Yu H, Parkash V, Lu L, Gaffney D, Dicker AP, Weidhaas J. The KRAS-Variant and miRNA Expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905. PLOS ONE 2014, 9: e94167. PMID: 24732316, PMCID: PMC3986055, DOI: 10.1371/journal.pone.0094167.Peer-Reviewed Original ResearchConceptsEndometrial cancer riskType 2 endometrial cancerEndometrial cancerKRAS-variantCancer riskLymphovascular invasionSurvival outcomesTumor biologyType 1 endometrial cancerEndometrial cancer trialsOverall survival rateMiRNA expressionAge-matched controlsCase-control analysisFunctional germline variantsClinical characteristicsPatient ageTumor characteristicsCancer trialsTumor specimensSurvival rateType 1Germline variantsMiRNA expression levelsCancer
2011
Genotypes and phenotypes of IGF-I and IGFBP-3 in breast tumors among Chinese women
Qian B, Zheng H, Yu H, Chen K. Genotypes and phenotypes of IGF-I and IGFBP-3 in breast tumors among Chinese women. Breast Cancer Research And Treatment 2011, 130: 217. PMID: 21562710, DOI: 10.1007/s10549-011-1552-9.Peer-Reviewed Original ResearchConceptsBreast cancer riskIGFBP-3 genotypesIGFBP-3 single nucleotide polymorphismsCancer riskChinese womenIGFBP-3Single nucleotide polymorphismsBreast cancerBreast tumorsTumor samplesLocal breast tissuesBreast cancer patientsIGF-I activityER-negative tumorsUnconditional logistic regressionCase-control studyFresh tumor samplesAge-matched controlsWilcoxon rank sum testRank sum testHigher peptide levelsIGFBP-3 geneIGF-I geneNegative tumorsCancer patients